📊 NXTC Key Takeaways
Is NextCure, Inc. (NXTC) a Good Investment?
NextCure shows impressive revenue growth of 252.6% YoY, but remains deeply unprofitable with operating margins of -257.5% and is burning $50.1M in annual free cash flow against only $26M in cash reserves, creating critical funding risk within 6-12 months. While the debt-free balance sheet and strong early revenue traction are positive, the company's cash runway does not support path to profitability without additional capital raises.
Why Buy NextCure, Inc. Stock? NXTC Key Strengths
- Strong revenue growth momentum at 252.6% YoY indicating market traction and commercialization progress
- Robust liquidity position with 4.14x current ratio and $26M cash providing operational flexibility
- Clean balance sheet with zero long-term debt eliminates leverage risk and financial distress concerns
NXTC Stock Risks: NextCure, Inc. Investment Risks
- Severe negative cash flow with -$50.1M free cash flow annually coupled with only $26M cash reserves creates acute liquidity risk with 6-12 month runway
- Operating losses of -$57.6M and net margin of -249.5% demonstrate business model not yet sustainable or approaching profitability
- High dilution from likely future capital raises required to fund ongoing losses and R&D spend
Key Metrics to Watch
- Operating cash burn rate and months of cash runway remaining
- Gross margin realization and product-level unit economics as commercialization scales
- Path to positive operating cash flow and timeline to profitability
NextCure, Inc. (NXTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.14x current ratio provides a solid financial cushion.
NXTC Profit Margin, ROE & Profitability Analysis
NXTC vs Healthcare Sector: How NextCure, Inc. Compares
How NextCure, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NextCure, Inc. Stock Overvalued? NXTC Valuation Analysis 2026
Based on fundamental analysis, NextCure, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NextCure, Inc. Balance Sheet: NXTC Debt, Cash & Liquidity
NXTC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NextCure, Inc.'s revenue has grown significantly by 253% over the 5-year period, indicating strong business expansion. The most recent EPS of $-23.88 indicates the company is currently unprofitable.
NXTC Revenue Growth, EPS Growth & YoY Performance
NXTC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $22.4M | $9.7M | $-0.59 |
| Q2 2021 | $22.4M | -$2.8M | N/A |
| Q1 2021 | $22.4M | $9.2M | $0.33 |
| Q3 2020 | $1.6M | -$6.2M | N/A |
| Q2 2020 | $1.4M | -$2.8M | N/A |
| Q1 2020 | $1.4M | -$6.2M | $0.33 |
| Q3 2019 | $1.6M | -$5.0M | N/A |
| Q2 2019 | $1.4M | -$5.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NextCure, Inc. Dividends, Buybacks & Capital Allocation
NXTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NextCure, Inc. (CIK: 0001661059)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NXTC
What is the AI rating for NXTC?
NextCure, Inc. (NXTC) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NXTC's key strengths?
Claude: Strong revenue growth momentum at 252.6% YoY indicating market traction and commercialization progress. Robust liquidity position with 4.14x current ratio and $26M cash providing operational flexibility.
What are the risks of investing in NXTC?
Claude: Severe negative cash flow with -$50.1M free cash flow annually coupled with only $26M cash reserves creates acute liquidity risk with 6-12 month runway. Operating losses of -$57.6M and net margin of -249.5% demonstrate business model not yet sustainable or approaching profitability.
What is NXTC's revenue and growth?
NextCure, Inc. reported revenue of $22.4M.
Does NXTC pay dividends?
NextCure, Inc. does not currently pay dividends.
Where can I find NXTC SEC filings?
Official SEC filings for NextCure, Inc. (CIK: 0001661059) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NXTC's EPS?
NextCure, Inc. has a diluted EPS of $-19.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NXTC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NextCure, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NXTC stock overvalued or undervalued?
Valuation metrics for NXTC: ROE of -159.8% (sector avg: 15%), net margin of -249.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NXTC stock in 2026?
Our dual AI analysis gives NextCure, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NXTC's free cash flow?
NextCure, Inc.'s operating cash flow is $-49.6M, with capital expenditures of $474.0K. FCF margin is -223.8%.
How does NXTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -249.5% (avg: 12%), ROE -159.8% (avg: 15%), current ratio 4.14 (avg: 2).